Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast pediatric fibrosing interstitial lung disease study
jRCT2031260056Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of nerandomilast in pulmonary fibrosis (PF) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration curve at steady state and Treatment-emergent adverse event occurrence. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
nerandomilast
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on jRCT2031260056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260056.